Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Period	fcf
2015-12-31	$183.87M
2016-12-31	-$175.86M
2017-12-31	-$185.62M
2018-12-31	-$148.70M
2019-12-31	$113.74M
2020-12-31	$28.34M
2021-12-31	-$88.24M
2022-12-31	-$90.18M
2023-12-31	-$162.37M
2024-12-31	-$179.81M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LXRX	$1.69	+5.31%	1.89M
3
4
5

Lexicon Pharmaceuticals Inc. (LXRX) Free Cash Flow

Free Cash Flow Data

Get Lexicon Pharmaceuticals Inc. Data in Excel

More LXRX Financial Data